Zobrazeno 1 - 10
of 14
pro vyhledávání: '"José Germán Sánchez-Hernández"'
Autor:
Paula Zapata-Cobo, Sara Salvador-Matín, Marta Velasco, Laura M. Palomino, Susana Clemente, Oscar Segarra, Ana Moreno-Álvarez, Ana Fernández-Lorenzo, Begoña Pérez-Moneo, Montse Montraveta, Cesar Sánchez, Mar Tolín, Inés Loverdos, María José Fobelo, Victor Manuel Navas-López, Lorena Magallares, Ruth García-Romero, José Germán Sánchez-Hernández, Alejandro Rodríguez, Ferrán Bossacoma, María Jesús Balboa, Enrique Salcedo, María Sanjurjo-Sáez, Luis A. López-Fernández
Publikováno v:
Pharmacological Research, Vol 196, Iss , Pp 106938- (2023)
Externí odkaz:
https://doaj.org/article/29237a28c7fb4acf97d7fc04e6eb47d0
Autor:
Paula Zapata-Cobo, Sara Salvador-Martín, Marta Velasco, Laura M. Palomino, Susana Clemente, Oscar Segarra, Ana Moreno-Álvarez, Ana Fernández-Lorenzo, Begoña Pérez-Moneo, Montserrat Montraveta, Cesar Sánchez, Mar Tolín, Inés Loverdos, María Jesús Fobelo, Victor Manuel Navas-López, Lorena Magallares, Ruth García-Romero, José Germán Sánchez-Hernández, Alejandro Rodríguez, Ferrán Bossacoma, María Jesús Balboa, Enrique Salcedo, María Sanjurjo-Sáez, Luis A. López-Fernández
Publikováno v:
Pharmacological Research, Vol 194, Iss , Pp 106859- (2023)
Few genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel disease (IBD), and even fewer have been identified in the pediatric population. However, it would be of considerable clinical interest to identify and validate g
Externí odkaz:
https://doaj.org/article/932b1c7582b3485494608f6bff4859d4
Autor:
Oscar Segarra, Elena Aznal, Antonio Millán-Jiménez, Francisco J. Eizaguirre, María Jesús Balboa-Vega, Gemma Pujol-Muncunill, Alejandro Rodriguez-Martinez, Rafael González de Caldas, Concepción Alvarez-Vayo, Carmen Gallego-Fernández, Judith Abarca-Zabalía, Susana Clemente, Rosana Muñoz-Codoceo, Mar Tolin, Javier Viada, Víctor Manuel Navas-López, Ana Moreno-Álvarez, César Sánchez, María Sanjurjo-Sáez, Inés Loverdos, Lorena Magallares, José Germán Sánchez-Hernández, Sara Salvador-Martín, Alfonso Solar-Boga, Eva Martínez-Ojinaga, Ferrán Bossacoma, Luis A. López-Fernández, Vicente Merino-Bohórquez, R. García-Romero, José A. Blanca-García
Publikováno v:
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
AIMS: Identifying DNA variants associated with trough serum anti-tumour necrosis factor (TNF) levels could predict response to treatment in inflammatory bowel disease (IBD). To date, no specific studies have been performed in children. The aim of thi
Autor:
Aranzazu Zarzuelo-Castañeda, Noemí Rebollo, Diego Peña-Lorenzo, José Germán Sánchez-Hernández
Publikováno v:
Annals of clinical biochemistry. 58(6)
Background Therapeutic drug monitoring (TDM) of voriconazole is recommended for personalizing doses. The objective of this study was to compare the enzyme immunoassay developed by ARKTM Diagnostics Inc. for the quantification of voriconazole adapted
Autor:
José Germán Sánchez-Hernández, Nerea Martín-Gutiérrez, Alejandra F Pordomingo, Noemí Rebollo, Fernando Muñoz, Otero Mj
Publikováno v:
Eur J Hosp Pharm
OBJECTIVE: Switching patients from the originator infliximab to a biosimilar is a measure to expand access to treatments and counteract its negative impact on healthcare budgets. However, industry-independent long-term studies on the effect of switch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f16e9d3e16959a58f63f1f566a045d8f
https://europepmc.org/articles/PMC9251170/
https://europepmc.org/articles/PMC9251170/
Autor:
N Martín-Gutiérrez, José Germán Sánchez-Hernández, MJ Otero-Lopez, A Fernández-Pordomingo, N Rebollo-Diaz, JF Muñoz-Núñez, V Recarey-Gerpe
Publikováno v:
National Poster Prize Winners.
Background Debate on the use of biosimilars focuses on the therapeutic efficacy and safety of switching between biosimilars and their reference products. Purpose To determine the clinical results and pharmacokinetic behaviour of switching from origin
Autor:
Noemí Rebollo, Ana Martín-Suárez, Fernando Muñoz, M Victoria Calvo, José Germán Sánchez-Hernández
Publikováno v:
Br J Clin Pharmacol
AIMS: Therapeutic drug monitoring (TDM) of trough serum infliximab concentrations has been mainly used in case of loss of response in patients with inflammatory bowel disease (IBD). The aim of this study was to evaluate the effectiveness and safety o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f85f0a14ab4cdfed54381f8f903f6eba
https://europepmc.org/articles/PMC7256129/
https://europepmc.org/articles/PMC7256129/
Autor:
Noemí Rebollo, Fernando Muñoz, Jonás Samuel Pérez-Blanco, José Germán Sánchez-Hernández, Vanessa Prieto, M. V. Calvo
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 150
Inflammatory bowel disease (IBD) is commonly treated with adalimumab. The main objective of the study was to develop a population pharmacokinetic model of adalimumab in IBD patients evaluating the potential biomarkers of disease activity and other fa
Autor:
Xandra García-González, José A. Blanca-García, María Sanjurjo-Sáez, Oscar Segarra, Vicente Merino-Bohórquez, Elena Aznal, María Jesús Balboa-Vega, Ana Moreno-Álvarez, Rafael González de Caldas, José Germán Sánchez-Hernández, Antonio Millán-Jiménez, Susana Clemente, Alejandro Rodriguez-Martinez, María J. Fobelo, Lorena Magallares, R. García-Romero, Víctor Manuel Navas-López, Gemma Pujol-Muncunill, Javier Viada, Concepción Alvarez-Vayo, Mar Tolin, Ricardo Torres-Peral, César Sánchez, Francisco J. Eizaguirre, Alfonso Solar-Boga, Ferrán Bossacoma, Luis A. López-Fernández, Eva Martínez-Ojinaga, Rosana Muñoz-Codoceo, Sara Salvador-Martín, Inés Loverdos, Carmen Gallego-Fernández
Publikováno v:
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
OBJECTIVES: Inflammatory bowel disease (IBD) is more complex in children and they will have to live with the disease for much longer. For this reason, it is necessary to optimize treatment. The polymorphisms associated with the response to anti-tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecf22153d99369d66cc05501deea2d60
https://journals.lww.com/jpgn/Fulltext/2020/10000/Genetic_Predictors_of_Long_term_Response_to.18.aspx
https://journals.lww.com/jpgn/Fulltext/2020/10000/Genetic_Predictors_of_Long_term_Response_to.18.aspx
Autor:
Lourdes Vázquez-López, José Germán Sánchez-Hernández, Noemí Rebollo, Otero Mj, Aranzazu Zarzuelo-Castañeda, Diego Peña-Lorenzo, Jonás Samuel Pérez-Blanco
Publikováno v:
European Journal of Pharmaceutical Sciences. 168:106049
Background Posaconazole is an antifungal agent extensively used as a prophylaxis for invasive fungal infections (IFIs) in allogeneic stem cell transplant (SCT) recipients. Low posaconazole concentrations have been associated with reduced clinical res